2-[4-fluoro-4-[[3,4,5-tris(phenylmethoxy)piperidin-1-yl]methyl]piperidin-1-yl]-1,3-benzothiazole
C39H42FN3O3S — CID 157039190
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-[4-fluoro-4-[[3,4,5-tris(phenylmethoxy)piperidin-1-yl]methyl]piperidin-1-yl]-1,3-benzothiazole
2-[4-fluoro-4-[[3,4,5-tris(phenylmethoxy)piperidin-1-yl]methyl]piperidin-1-yl]-1,3-benzothiazole (PubChem CID 157039190) has the molecular formula C39H42FN3O3S and a molecular weight of 651.85 g/mol. Its IUPAC name is 2-[4-fluoro-4-[[3,4,5-tris(phenylmethoxy)piperidin-1-yl]methyl]piperidin-1-yl]-1,3-benzothiazole.
Molecular Properties
| Compound Name | 2-[4-fluoro-4-[[3,4,5-tris(phenylmethoxy)piperidin-1-yl]methyl]piperidin-1-yl]-1,3-benzothiazole |
|---|---|
| PubChem CID | 157039190 |
| Molecular Formula | C39H42FN3O3S |
| Molecular Weight | 651.85 g/mol |
| Exact Mass | 651.29 |
| IUPAC Name | 2-[4-fluoro-4-[[3,4,5-tris(phenylmethoxy)piperidin-1-yl]methyl]piperidin-1-yl]-1,3-benzothiazole |
| SMILES | FC1(CN2CC(OCc3ccccc3)C(OCc3ccccc3)C(OCc3ccccc3)C2)CCN(c2nc3ccccc3s2)CC1 |
| InChI | InChI=1S/C39H42FN3O3S/c40-39(20-22-43(23-21-39)38-41-33-18-10-11-19-36(33)47-38)29-42-24-34(44-26-30-12-4-1-5-13-30)37(46-28-32-16-8-3-9-17-32)35(25-42)45-27-31-14-6-2-7-15-31/h1-19,34-35,37H,20-29H2 |
| InChIKey | KMZLTYXSBIWZHK-UHFFFAOYSA-N |
| XLogP | 7.68 |
| TPSA | 47.06 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 12 |
| Heavy Atoms | 47 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 651.85 |
| LogP ≤ 5 | 7.68 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 157039190 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.